Zyvox is used for treating adults with certain serious bacterial infections that are often resistant to other antibiotics.

Package	Price	Per Item	Savings	Order
10 pills x 600 mg	$138.02	Only $13.80 per pill	You Save $0.00
20 pills x 600 mg	$245.79	Only $12.29 per pill	You Save $30.25
30 pills x 600 mg	$318.41	Only $10.62 per pill	You Save $95.70

Pfizer Incorporated (NYSE: PFE) is a big pharmaceutical company, ranking number one in sales in the world. The company is based in New York New Zealand urban area, and its research headquarters is in Groton, Connecticut. It produces the number-one selling drug Lipitor (atorvastatin, old to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the word-of-mouth antifungal medication Diflucan (fluconazole), the long-acting antibiotic Zithromax (azithromycin), the jet-known erectile dysfunction drug Viagra (sildenafil citrate), and the anti explosive Celebrex (celecoxib) (also known as Celebra in some countries outside USA and Canada, for the most part in South America).

Pfizer's shares were made a component of the Dow Jones Industrial Customary on April 8, 2004.

On January 26, 2009, Pfizer agreed to buy pharmaceutical giant Wyeth for US$68 billion, a take care of financed with cash, shares and loans.

History

Pfizer is named after German-American cousins Charles Pfizer and Charles Erhardt (they were from day one from Ludwigsburg, Germany) who launched their chemicals business Charles Pfizer and Following from a building at the intersection of Harrison Avenue and Bartlett Street in Williamsburg, Brooklyn in 1849. There, they produced an antiparasitic called santonin. This was an adjacent success, although it was the production of citric acid that really kick-started Pfizer's vegetation in the 1880s. Pfizer continued to buy property to expand its lab and factory on the block bounded by Bartlett Concourse; Harrison Avenue; Gerry Street; and Flushing Avenue. That facility is even so utilized for backshop purposes. Pfizer established its original administrative headquarters at 81 Maiden Lane in Manhattan.

By 1910, sales totaled approximately $3 million, and Pfizer became established as an expert in fermentation technology. These skills were applied to the lump production of penicillin during World War II, in response to an appeal from the U.S. government. The antibiotic was urgently needed to scrutinize injured Allied soldiers, and it soon became known as "the miracle drug". In in point of fact, most of the penicillin that went ashore with the troops on D-Day was made by Pfizer.

By the 1950s, Pfizer was established in Belgium, Brazil, Canada, Cuba, Iran, Mexico, Panama, Puerto Rico, Turkey and the Common Kingdom.

During the 1980s and 1990s Pfizer underwent a period of growth ceaseless by the discovery and marketing of multiple successful drugs (Zoloft, Lipitor, Norvasc, Zithromax, Aricept, Diflucan, Viagra).

In 2005, Pfizer was bulk 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.

Corporate build

Current members of the board of directors of Pfizer are: Michael S. Brown, M. Anthony Burns, Robert Burt, Don Cornwell, William H. Gray, Constance Horner, William Howell, Stanley Ikenberry, Jeff Kindler (chairman), George Lorch, Dana Mead, Ruth J. Simmons, and William Steere.

• Chief Top banana Officer (CEO): Jeff Kindler
• Vice Chairman: David L. Shedlarz
• President of Worldwide Pharmaceutical Operations: Ian Pore over
• President of Global R&D: Martin Mackay
• 2007 Pharmacist of the Year: Mike Militello, Pharm.D., BCPS

Pfizer is organized into four divisions: Human Healthfulness ($44.28B in 2005 sales), Consumer Healthcare ($3.87B in 2005 sales), Zoological Health ($2.2B in 2005 sales), and Corporate Groups (which includes right, finance, and HR). On June 26, 2006, Pfizer announced that it would sell its Consumer Healthcare component (famous for well-known brands like Listerine, Nicorette, Visine, Sudafed and Neosporin) to Johnson & Johnson for $16.6B.

Union and acquisition activity

Pfizer was relatively conservative with regard to mega-mergers inclusive of stock-for-stock transactions through most of its history until 2000. In that year, William Steere retired from the presence and was succeeded by Henry McKinnell. As can be noted with any stock analysis tool, Pfizer's per portion price (adjusted for splits) went from about $50 to $30 from 1999 to 2006 during McKinnell's residency. With roughly 7 billion shares outstanding, this reflects a loss in value of $140 billion beneath the waves McKinnell's leadership pursuing a strategy of growth via stock for stock acquisition. Myriad industry analysts, however, criticize McKinnell for diluting shareholder value with these overpriced stock-for-stock acquisitions that obviously paid a premium for the underlying value of the acquired concern. Furthermore, internal contributions to the pipeline did not replace declining value nor did these M&A activities. McKinnell received memorial compensation which he staunchly defended against critics.

Warner-Lambert / Parke-Davis / Agouron

In 2000, Pfizer merged with Warner-Lambert and acquired emotional rights to Lipitor (atorvastatin), the blockbuster statin previously jointly marketed by Warner-Lambert and Pfizer. Warner-Lambert was based in Morris Plains, New Jersey, where departed headquarters became a major base of operations for Pfizer. The majority of the facility, and Pfizer's consumer healthcare jurisdiction, was sold to Johnson and Johnson in 2006 for $16.6 billion.

Parke-Davis was acquired by Warner-Lambert in 1970, which in circle was merged into Pfizer in 2000. The headquarters of Parke-Davis was sold a number of years ago. Pfizer sold the near-174-acre Parke-Davis into complex in Ann Arbor, Michigan to the University of Michigan in 2008 for $108 million. It would 'accelerate the distention' of the university's research activities. Some renovations would be needed' and create 2,000 new explore jobs, the university said.

Agouron Pharmaceuticals was acquired by Warner Lambert in 1999 and is now a subsidiary of Pfizer. Nelfinavir (Viracept), an antiretroviral narcotize used in the treatment of the human immunodeficiency virus (HIV), was developed by Agouron Pharmaceuticals as have of a joint venture with Japan Tobacco, Inc.

Pharmacia / Upjohn / Searle

Searle was founded in Omaha, Nebraska, in 1888. The sink was Gideon Daniel Searle. In 1908, the company was incorporated in Chicago. In 1941, the institution established headquarters in Skokie, Illinois. It was acquired by the Monsanto company, headquartered in St. Louis, in 1985.

The Upjohn Retinue was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical credo. The company was originally formed to make friable pills, which were specifically designed to be definitely digested.

In 1995, Upjohn merged with Pharmacia, to form Pharmacia & Upjohn. Pharmacia was created in April 2000 entirely the merger of Pharmacia & Upjohn with the Monsanto Company and its G.D. Searle unit. The merged attendance was based in Peapack, New Jersey. The agricultural division was spun off from Pharmacia, as Monsanto, in preparation for the inseparable of the acquisition by Pfizer.

In 2002, Pfizer merged with Pharmacia, a competitor, to behoove the largest pharmaceutical company in the world. The merger was again driven in part by the wish to acquire full rights to a blockbuster product, this time Celebrex (celecoxib), the COX-2 demanding inhibitor previously jointly marketed by Searle (acquired by Pharmacia) and Pfizer. In the ensuing years, Pfizer commenced with a gigantic restructuring resulting in numerous site closures and loss of jobs including: Terre Haute, IN; Holland, MI; Groton, CT; Brooklyn, NY; Sandwich, UK and Puerto Rico.

In 2008, Pfizer announced 275 job cuts at the Kalamazoo manufacturing easiness. Kalamazoo was previously the world headquarters for the Upjohn Company.

SUGEN

SUGEN , customarily written with foremost letters, was founded in 1991 in Redwood City, California, as a partnership between the laboratories of Joseph Schlessinger at New York University Medical Lyceum and Axel Ullrich at the Max Planck Institute of Biochemistry, with Steven Evans-Freke as a third co-trip. The name, SUGEN, is derived from combining the first "S" in Schlessinger followed by the "U" in Ullrich with "GEN" - a commonly reach-me-down suffix by biotech companies (short for "GENetics" or "GENesis"). The focus of the get-up-and-go was to develop drugs targeting intracellular signaling pathways to treat cancer. Specifically, the comrades sought to discover competitive ATP small-molecule kinase inhibitors which design common cancer pathways. Pharmacia acquired SUGEN in 1999, which merged with the pharmaceutical apportionment of Monsanto in 2000 and was purchased by Pfizer in 2003. In 1999, Pharmacia advanced two of SUGEN's edge compounds into clinical trials for colon cancer: SU5416 (Semaxanib) and SU6668; the trials were discontinued but a third and closely kindred compound named SU11248 was pursued. SUGEN's laboratories were closed in 2003 as be involved in of the reorganization following Pfizer's purchase of Pharmacia. From the acquisition, SUGEN compounds SU11248 and SU14813 entered Pfizer's imminent. In January 2006, SU11248 was approved by the FDA for treatment of GIST and RCC, and it is now marketed as Sutent (sunitinib). Sutent is loaded by Plant in Ascoli Piceno, Italy.

Wyeth

On 26 January 2009, after more than a year of talks between the two companies, Pfizer agreed to buy pharmaceuticals rival Wyeth for a combined US$68 billion in mazuma change, shares and loans, including some US$22.5 billion lent by five outstanding Wall Street banks. This deal would cement Pfizer's employment as the largest pharmaceutical company in the world, with the merged company generating to US$20 billion in cash each year, and represents the largest corporate union since AT&T and BellSouth's US$70 billion deal in March 2006. Wyeth's administration team is expected to depart following the merger. The combined company could redeem US$4 billion annually through the streamlining of operations; however, as part of the deal, both companies ought to repatriate billions of dollars in revenue from foreign sources to the United States, which longing result in higher tax costs. Pfizer was advised in the merger by Goldman Sachs, JPMorgan Pursuit and Barclays; Wyeth was advised by Morgan Stanley and Evercore Partners.

Crtitics of the merging

The merger received a vast array of criticism. Harvard Business School’s Gary Pisano told the WSJ:

"The compact disc of big mergers and acquisitions in Big Pharma has just not been good. There’s just been an gross amount of shareholder wealth destroyed."

The Warner-Lambert and Pharmacia mergers do not show to have achieved gains for shareholders so it is unclear who will benefit from the Wyeth-Pfizer consolidation to many critics.

Products

Pfizer manufactures pharmaceutical medications and has an annual goods marketing budget of $3 billion, which was the fourth-largest in the U.S. as of 2003. Pfizer employs 38,000 sales representatives worldwide.

In 2004, Pfizer’s Zoloft sales totaled $3.15 billion, contributing to 6.5% of Pfizer’s gross revenue for 2004 and making it one of 19 drugs that generated more than $2 billion in revenues in the Connected States. In 2005, Zoloft sales totaled $3.5 billion, helping to divulge Pfizer one of the biggest drug makers in the world with approximately $51.3 billion in profits for 2005. In 2005 Pfizer Inc. spent $7.4 billion on research and development, making Pfizer International Research and Development the largest pharmaceutical research and development organization.

On September 24, 2007, Pfizer Inc. announced that the European Commission approved Celsentri (generic christen, maraviroc and as Selzentry in the United States). Industry experts did forecast annual Celsentri sales of $500 million by 2011.

Occurrence of torcetrapib

Development of torcetrapib, a drug that increases production of HDL, or "good cholesterol", which reduces LDL deliberating to be correlated to heart disease, was cancelled on December 2, 2006. During a clinical irritation test that involved 15,000 patients, more patients than expected died in the gathering that took the medicine. A 60% increase in deaths was observed among patients irresistible torcetrapib and Lipitor versus taking Lipitor alone; there was no suggestion that the results called into query the safety of Lipitor. Pfizer has lost nearly $1 billion in investments on the failed anaesthetize, and December has seen the stocks and market value of the company plummet.

Pharmaceuticals

The following is a inventory of key prescription pharmaceutical products. The names shown are all registered trademarks of Pfizer Inc.

• Accupril (quinapril) for hypertension treatment.
• Aricept (donepezil) for Alzheimer's virus.
• Aromasin (exemestane) for the prevension of breast cancer and the prevension of osteoporosis and menopause for women.
• Bextra (Valdecoxib) for arthritis.
• Ben-Gay a sports cream co marketed by Johnson and Johnson, and McNeil Laboratories.
• Caduet (amlodipine) and (atorvastatin) for cholesterol and hypertension.
• Camptosar (irinotecan) for cancer and Chemotherapeutic agents.
• Celebrex (celecoxib) for arthritis.
• Chantix (Varenicline) for Nicotinic agonists, and anti nicotine drugs.
• Cefobid a cephalosporin antibiotic.
• Depo-Medrol (methylprednisolone) for asthma.
• Solu-Medrol (methylprednisolone) for asthma.
• Depo Provera for beginning control.
• Detrol, and Detrol LA (tolterodine), for bladder control problems.
• Diflucan (fluconazole) for antifungal narcotize.
• Ellence (epirubicin) for cancer and chemotherapy drug.
• Eraxis (anidulafungin) for antifungal medicate.
• Exubera (inhalable insulin) for diabetes, and insulin therapies.
• Flagyl (metronidazole) for bacterial and protozoal infections.
• Genotropin (Vegetation hormone) for N/A.
• Geodon (ziprasidone) for schizophrenia and bipolar disorder.
• Inspra (eplerenone) for diuretics.
• Lipitor (atorvastatin) for cholesterol.
• Lyrica (pregabalin) for neuropathic torture.
• Macugen (pegaptanib) for N/A
• Norvasc (amlodipine) for hypertension
• Neurontin (gabapentin) for neuropathic annoyance.
• Rebif (interferon beta-1a) for Multiple Sclerosis
• Relpax (eletriptan) for including the sulfonamide dispose of migrane .
• Rescriptor (delavirdine) for N/A.
• Selzentry (maraviroc) for N/A.
• Somavert (pegvisomant) for N/A.
• Sutent (sunitinib) for cancer and chemotherapy dope.
• Spiriva (tiotropium) for asthma.
• Tikosyn (dofetilide) for atrial fibrillation and flutter.
• Vfend (voriconazole) for antifungal medicate.
• Viagra (sildenafil) for erectile dysfunction.
• Viracept (nelfinavir) for AIDS.
• Xalatan (latanoprost) for glaucoma
• Xalacom latanoprost and timolol Medication for glaucoma.
• Xanax and Xanax XR (alprazolam) for foreboding and panic disorders.
• Zoloft (sertraline) for an antidepressant.
• Zyrtec (cetirizine) for allergies.
• Zyvox (linezolid) for antibiotics.

Animalistic health brands

The following is a partial list of Animal Health brands manufactured by Pfizer:

• Bovi-Guard Gold
• Cerenia
• Convenia
• Dectomax
• Draxxin
• Excede
• Excenel
• Inovocox
• Mycitracin
• Pirsue
• A180
• Rebellion Pet Medicine
• Rimadyl
• Simplicef
• Slentrol
• Solitude IGR
• Spectramast
• Stellamune
• Stronghold

Legislation and legal remedy

Pfizer is party to a number of suits stemming from companies it has acquired or merged with, including asbestos legal remedy as well as litigation stemming from its medicinal products.

Kelo case

Pfizer's notice in obtaining property in New London, Connecticut for expanded facilities led to the Kelo v. New London lawsuit before the U.S. Supreme Court.

Quigley Co.

Pfizer acquired Quigley in 1968, and the breaking up sold asbestos-containing insulation products until the early 1970s. Asbestos victims and Pfizer sire been negotiating a settlement deal which calls for Pfizer to pay $430 million to 80 percent of existing plaintiffs. It intention also place an additional $535 million into an asbestos settlement delegate that will compensate future plaintiffs as well as the remaining 20 percent of contemporary plaintiffs with claims against Pfizer and Quigley. The compensation deal is significance $965 million all up.Of that $535 million, $405 million is in a 40-year note from Pfizer, while $100 million intent come from insurance policies.

Bjork-Shiley heart valve

Pfizer purchased Shiley in 1979 at the commencement of its Convexo-Concave valve ordeal, involving the Bjork-Shiley heart valve. Almost 500 people died when defective valves failed and, in 1994, the Communal States ruled against Pfizer for ~$200 million.

Tort reform legislation contributions

Pfizer proposed a ban on all lawsuits against manufacturers of stiff implant parts which was proposed in the United States Congress as part of tort rehabilitate legislation.

Off-label promotional practices

Access to pharmaceutical industry documents has revealed marketing strategies acclimated to to promote Neurontin for off-label use. In 1993, the US Food and Drug Administration (FDA) approved gabapentin (Neurontin, Pfizer) not for treatment of seizures. Warner-Lambert, which merged with Pfizer in 2000, inured to activities not usually associated with sales promotion, including continuing medical indoctrination and research, sponsored articles about the drug for the medical literature, and alleged halt of unfavorable study results, to promote gabapentin. Within 5 years the drug was being considerably used for the off-label treatment of pain and psychiatric conditions. In 2004, Warner-Lambert admitted to charges that it violated FDA regulations by promoting the narcotic for pain, psychiatric conditions, migraine, and other unapproved uses, and paid $430 million to make up one's mind criminal and civil health care liability charges. Today it is a mainstay cure for migraines, even though it was not approved for such use in 2004.

Nigeria

In 1996, an outbreak of measles, cholera, and bacterial meningitis occurred in Nigeria. Pfizer representatives traveled to Kano, Nigeria to serve in treating the affected population. An experimental antibiotic, trovafloxacin, was administered to approximately 200 children. Neighbourhood Kano officials report that more than 50 children died from infection, while sundry others developed mental and physical deformities. In 2001, families of the children, as without difficulty completely as the governments of Kano and Nigeria, filed lawsuits regarding the treatment. According to the lawsuits, Pfizer administered the trovafloxacin (now marketed as Trovan) without parental assent. The lawsuits also accuse Pfizer of using the outbreak to perform unapproved forgiving testing, as well as allegedly under-dosing a control group being treated with stock antibiotics in order to skew the results of the trial in favor of Trovan. Pfizer denied these claims, and afterward produced an approval letter for testing from the Nigerian Ethics Committee; the Nigerian management claims it is a fake.

In 2007, Pfizer published a Statement of Defense letter. The communication makes several claims which deserve mention:

The figure in NGN is approximately $216,000 in 1996 US dollars (USD).

The more probably reason for Pfizer's insistence on the oral form is the result of testing trovafloxacin intravenously in 1995, which bring about that the drug precipitated in saline, making it ineffective in patients receiving IV fluids. This is inferred from an FDA communication to ex-CEO William C. Steere, at all events Trovan's compatibility with saline etc., which was omitted from Trovan's labeling until January 1999.

According to the figures premised by their own defense, 94.4% of patients receiving Trovan survived, while solitary 89.3% of untreated Nigerians survived. This is not a statistically significant difference, i.e. the good fortune of the drug was negligible and possibly circumstantial.

In June 1999, the FDA released a public form statement warning against the use of Trovan except in life-or-death situations, due to elevated risk of liver failure. In some cases, liver damage occurred after one two days of treatment.

Research and development

Pfizer's human research and development syndicate is headquartered in New London, CT while their animal health research and development body is headquartered in Kalamazoo, Michigan. The company has R&D labs in the following locations: Groton, Connecticut; Sandwich, England; Nagoya, Japan; Amboise, France; La Jolla, California; Cambridge, Massachusetts; Kalamazoo, Michigan; St. Louis, Missouri.

Spending $8.1 billion in investigating & development (R&D) in 2007, Pfizer has the industry's largest pharmaceutical R&D organization: Pfizer Broad Research and Development.

In 2007, Pfizer announced plans to close or sell on the Loughbeg API structure, located at Loughbeg, Ringaskiddy Co.Cork Ireland by mid to end of 2008

In 2007, Pfizer announced plans to barrel close the Ann Arbor, Nagoya and Amboise Research facilities by the end of 2008, eliminating 2,160 jobs and idling the $300-million dollar Michigan alacrity, which had seen millions of dollars of expansion in recent years.

On June 18, 2007 Pfizer announced it choose move the Sandwich, England Animal Health Research (VMRD) division to Kalamazoo, Michigan.

Environmental dossier

According to the EPA, Pfizer is among the top ten companies in America with the most numerous emissions sources. Their 70-acre (280,000 m ² ) impress in Groton, Connecticut, is home to a 20-acre (81,000 m ² ) landfill and two wastewater lagoons, adding to contamination in the area. According to the EPA, Pfizer is a main threat to the health of the residents and the environment of the New London range because of its toxic emissions into the air and water. The EPA has cited Pfizer on multiple occasions for outlawed discharges into the Thames River and for hazardous waste violations on site. In appendix, in June 2002, Pfizer was responsible for a chemical explosion that injured seven people and caused the evacuation of onto 100 homes in the surrounding area.
Pfizer has also provided funding to the argumentative Competitive Enterprise Institute who have been criticized for releasing misleading advertisements claiming that pandemic warming is not a problem.

Employment and diversity

Pfizer received a 100% rating on the Corporate Coequality Index released by the Human Rights Campaign starting in 2004, the third year of the communication. In 2007, Pfizer's Canadian division was named one of Canada's Top 100 Employers, as published in Maclean's ammunition, the only research-based pharmaceutical company to receive this honor. In 2008, there was confrontation, including inquiries from members of Congress, around Pfizer's practice of replacing US workers with H-1b patron workers

AIDS involvement

Pfizer has been involved in controversies over the remedy Diflucan (generic name fluconazole). In 1998, a campaign by Thai public condition groups led to the elimination of the Pfizer monopoly on selling fluconazole in Thailand, and the price of the antifungal painkiller decreased from 200 baht to 6.5 baht in nine months, greatly expanding access to the medicine for AIDS patients. Faced with pressure for compulsory licenses to the Pfizer flagrant on this drug, Pfizer later established a program for limited access to the medicament in Africa.

"In the United States, 46 percent of all new HIV/AIDS cases occur in the South. From 2003–2006 the Pfizer Grounds has funded 23 innovative HIV/AIDS prevention programs and strengthened the capacity of community-based organizations to reach and be accurate their communities." Since 2003, Pfizer has committed a $3 Million donate toward supporting the Southern HIV/AIDS Prevention Initiative.

However, there are criticisms of the way Pfizer is testing its AIDS treat. "The European AIDS Treatment Group (EATG), collection of activists from 31 European Countries, said the plan of the trial for Pfizer's CCR5 inhibitor Maraviroc (previously known as UK-427,857) is putting people with HIV infection at unwanted risk of developing AIDS."

On June 20, 2007, Maraviroc received an approvable belles-lettres from the FDA advisory board. The letter was a product of expedited review of the novel HIV parathesis.

In 2001, Pfizer asked the U.S. government to pressure the Brazilian government against issuing compulsory licenses for the patents on the AIDS medicine nelfinavir.

AIDS drugs manufactured by Pfizer

• Viracept (nelfinavir mesylate)
• Selzentry/Celsentri (maraviroc)
• Rescriptor (delavirdine mesylate)

See also

• Peter Rost
• Viking Bjork

Notes and references

1. ^ "Pfizer 4Q Profit Falls but Beats Intention". Forbes. January 23, 2009 . http://www.forbes.com/feeds/ap/2008/01/23/ap4565943.html . Retrieved on 2008-02-14 .  
2. ^ "Presence Profile for Pfizer Inc (PFE)" . http://zenobank.com/index.php?symbol=PFE&page=quotesearch . Retrieved on 2008-10-01 .  
3. ^ Andrew Ross Sorkin and Inoperative Wilson (January 26, 2009). "Pfizer Agrees to Pay $68 Billion for Rival Dope Maker Wyeth". New York Times . http://www.nytimes.com/2009/01/26/affair/26drug.html .  
4. ^ ^{a b} Kenneth T. Jackson: The Encyclopedia of New York City : The New York True Society; Yale University Press; 1995. P. 895.
5. ^ Drinkard, Jim (2005-01-17). "Donors get trustworthy seats, great access this week". USA Today . http://www.usatoday.com/expos/washington/2005-01-16-inauguration-donors_x.htm . Retrieved on 2008-05-25 .  
6. ^ "Financing the inauguration". USA Today . http://www.usatoday.com/scandal/washington/2005-01-16-inaugural-donors_x.htm . Retrieved on 2008-05-25 .  
7. ^ "Some question inaugural's multi-million consequence tag". USA Today. 2005-01-14 . http://www.usatoday.com/news/washington/2005-01-14-price_x.htm . Retri
   We would feel happy if this article on Zyvox Buy proves its mettle by being productive and useful for you in your future endeavors on Zyvox Buy.

   Comments

   Previous Entries

   post date	category	title/description
   03.23.2009	Articles	1000 Cc Breast Augmentation
   03.23.2009	Articles	1000 Augmentin Xr
   03.23.2009	Articles	1000 Antiaging Hgh Hghcom Prime
   03.23.2009	Articles	1000 Antiaging Hgh Hghcom
   03.23.2009	Articles	1000 Antiaging Hgh Hgh Hghcom Prime

   Post Comments

   Name Email Your Comments